Recent Advances in Tuberculosis and Nontuberculous Mycobacteria Lung Disease.
10.4046/trd.2013.74.6.251
- Author:
Jae Seuk PARK
1
Author Information
1. Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. jspark@dankook.ac.kr
- Publication Type:Review
- Keywords:
Tuberculosis;
Nucleic Acid Amplification Techniques;
Linezolid;
Nontuberculous Mycobacteria
- MeSH:
Acetamides;
Incidence;
Lung;
Lung Diseases;
Mycobacterium;
Mycobacterium tuberculosis;
Nontuberculous Mycobacteria;
Nucleic Acid Amplification Techniques;
Oxazolidinones;
Rifampin;
Tuberculosis;
Linezolid
- From:Tuberculosis and Respiratory Diseases
2013;74(6):251-255
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tuberculosis (TB) is one of the largest health problems in the world today. And the incidence of nontuberculous mycobacteria (NTM) lung disease appears to be increasing worldwide. Recently, an automated, nucleic acid amplification assay for the rapid detection of both Mycobacterium tuberculosis and rifampin resistance was developed (Xpert MTB/RIF). And fixed-dose combinations of anti-TB drugs and linezolid have been introduced in the treatment of TB. And new NTM species, named Mycobacterium massiliense, which is very closely related to Mycobacterium abscessus was reported. In this review, these recent advances in the diagnosis and treatment of TB and clinical characteristics of M. massiliense lung disease are discussed.
